Rocket Pharmaceuticals (RCKT) News Today

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares are moving today on a mix of positive regulatory updates, a neutral broker consensus and ongoing legal challenges. Investors are reacting to new RMAT designations for its gene therapies, an average “Hold” rating from analysts, and multiple securities class action lawsuits tied to an FDA clinical hold.

• Positive Sentiment: FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601 for heart failure gene therapy on the back of positive Phase I data, driving a notable share gain. RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
• Positive Sentiment: The U.S. FDA also awarded RMAT status to RP-A601 for PKP2-arrhythmogenic cardiomyopathy, underscoring regulatory support for Rocket’s late-stage pipeline. Rocket Pharmaceuticals Receives FDA RMAT Designation for RP-A601
• Neutral Sentiment: Seventeen brokerages covering RCKT have given it an average “Hold” rating, reflecting cautious optimism on its clinical outlook. Receives Average Rating of "Hold" from Brokerages
• Negative Sentiment: An FDA clinical hold on the Phase 2 RP-A501 trial for Danon disease earlier in May led to a steep share plunge and has triggered a class action lawsuit filed by Hagens Berman. FDA Clinical Hold on RP-A501 Trial Triggers Stock Plunge and Class Action
• Negative Sentiment: Multiple law firms—including Levi & Korsinsky, Rosen, Bronstein Gewirtz, Pomerantz, The Gross Law Firm and Berger Montague—have filed or are soliciting lead plaintiff claims alleging securities fraud related to disclosures between February 27 and May 26, 2025. Class Action Filed Against Rocket Pharmaceuticals, Inc. – Levi & Korsinsky